Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): PMS-Ramipril Cap (02247917), PMS-Ramipril Cap (02247918), PMS-Ramipril Cap (02247919). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ramipril
23 general benefit · 1 not a benefit
Altace Cap · DIN 02221829 · 1.25 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Altace Cap · DIN 02221829
Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-06
Health Canada: Marketed since 2021-01-11 · brand ALTACE · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02221829)
Source record
DIN 02221829: Altace Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id SAV
Source form: None; strength: 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.0027; ministry $0.0708
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02221829
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43308
Interchangeable products
Apo-Ramipril Cap · DIN 02251515 · $0.0708
Auro-Ramipril Cap · DIN 02387387 · $0.0708
Co Ramipril Cap · DIN 02295482 · $0.0708
Jamp-Ramipril Cap · DIN 02331101 · $0.0708
Mar-Ramipril Cap · DIN 02420457 · $0.0708
PMS-Ramipril Cap · DIN 02295369 · $0.0708
PMSC-Ramipril Cap · DIN 02550202 · $0.0708
Pharma-Ramipril · DIN 02469057 · $0.0708
Ramipril Cap · DIN 02299372 · not recorded
Ramipril Cap · DIN 02308363 · $0.0708
Ran-Ramipril Cap · DIN 02310503 · $0.0708
Shortage status: resolved shortage (ended February 10, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02221829
Shortage record checked October 6, 2026
Apo-Ramipril Cap · DIN 02251515 · 1.25 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Ramipril Cap · DIN 02251515
Manufacturer: Apotex Inc.; listing date 2007-03-09
Health Canada: Marketed since 2006-12-12 · brand APO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Ramipril Cap: Formulary list price $0.07 per unit (the source does not state the unit; exact figure $0.0708). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02251515)
Source record
DIN 02251515: Apo-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id APX
Source form: None; strength: 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0708; ministry $0.0708
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02251515
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73644
Interchangeable products
Altace Cap · DIN 02221829 · $0.0708
Auro-Ramipril Cap · DIN 02387387 · $0.0708
Co Ramipril Cap · DIN 02295482 · $0.0708
Jamp-Ramipril Cap · DIN 02331101 · $0.0708
Mar-Ramipril Cap · DIN 02420457 · $0.0708
PMS-Ramipril Cap · DIN 02295369 · $0.0708
PMSC-Ramipril Cap · DIN 02550202 · $0.0708
Pharma-Ramipril · DIN 02469057 · $0.0708
Ramipril Cap · DIN 02299372 · not recorded
Ramipril Cap · DIN 02308363 · $0.0708
Ran-Ramipril Cap · DIN 02310503 · $0.0708
Shortage status: resolved shortage (ended February 29, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02251515
Shortage record checked October 6, 2026
Auro-Ramipril Cap · DIN 02387387 · 1.25 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Ramipril Cap · DIN 02387387
Manufacturer: Auro Pharma Inc.; listing date 2013-02-28
Health Canada: Marketed since 2012-09-13 · brand AURO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Ramipril Cap: Formulary list price $0.07 per unit (the source does not state the unit; exact figure $0.0708). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02387387)
Source record
DIN 02387387: Auro-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id AUR
Source form: None; strength: 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0708; ministry $0.0708
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02387387
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87297
Interchangeable products
Altace Cap · DIN 02221829 · $0.0708
Apo-Ramipril Cap · DIN 02251515 · $0.0708
Co Ramipril Cap · DIN 02295482 · $0.0708
Jamp-Ramipril Cap · DIN 02331101 · $0.0708
Mar-Ramipril Cap · DIN 02420457 · $0.0708
PMS-Ramipril Cap · DIN 02295369 · $0.0708
PMSC-Ramipril Cap · DIN 02550202 · $0.0708
Pharma-Ramipril · DIN 02469057 · $0.0708
Ramipril Cap · DIN 02299372 · not recorded
Ramipril Cap · DIN 02308363 · $0.0708
Ran-Ramipril Cap · DIN 02310503 · $0.0708
Shortage status: resolved shortage (ended March 17, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02387387
Shortage record checked October 6, 2026
PMSC-Ramipril Cap · DIN 02550202 · 1.25 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMSC-Ramipril Cap · DIN 02550202
Manufacturer: Pharmascience Inc.; listing date 2025-12-30
Health Canada: Marketed since 2025-10-03 · brand PMSC-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMSC-Ramipril Cap: Formulary list price $0.07 per unit (the source does not state the unit; exact figure $0.0708). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02550202)
Source record
DIN 02550202: PMSC-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id PMS
Source form: None; strength: 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0708; ministry $0.0708
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02550202
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103904
Interchangeable products
Altace Cap · DIN 02221829 · $0.0708
Apo-Ramipril Cap · DIN 02251515 · $0.0708
Auro-Ramipril Cap · DIN 02387387 · $0.0708
Co Ramipril Cap · DIN 02295482 · $0.0708
Jamp-Ramipril Cap · DIN 02331101 · $0.0708
Mar-Ramipril Cap · DIN 02420457 · $0.0708
PMS-Ramipril Cap · DIN 02295369 · $0.0708
Pharma-Ramipril · DIN 02469057 · $0.0708
Ramipril Cap · DIN 02299372 · not recorded
Ramipril Cap · DIN 02308363 · $0.0708
Ran-Ramipril Cap · DIN 02310503 · $0.0708
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550202
Shortage record checked October 6, 2026
Pharma-Ramipril · DIN 02469057 · 1.25 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Pharma-Ramipril · DIN 02469057
Manufacturer: Pharmascience Inc.; listing date 2018-09-27
Health Canada: Marketed since 2018-04-16 · brand PHARMA-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPharma-Ramipril: Formulary list price $0.07 per unit (the source does not state the unit; exact figure $0.0708). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02469057)
Source record
DIN 02469057: Pharma-Ramipril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id PMS
Source form: None; strength: 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0708; ministry $0.0708
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02469057
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95770
Interchangeable products
Altace Cap · DIN 02221829 · $0.0708
Apo-Ramipril Cap · DIN 02251515 · $0.0708
Auro-Ramipril Cap · DIN 02387387 · $0.0708
Co Ramipril Cap · DIN 02295482 · $0.0708
Jamp-Ramipril Cap · DIN 02331101 · $0.0708
Mar-Ramipril Cap · DIN 02420457 · $0.0708
PMS-Ramipril Cap · DIN 02295369 · $0.0708
PMSC-Ramipril Cap · DIN 02550202 · $0.0708
Ramipril Cap · DIN 02299372 · not recorded
Ramipril Cap · DIN 02308363 · $0.0708
Ran-Ramipril Cap · DIN 02310503 · $0.0708
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02469057
Shortage record checked October 6, 2026
Ramipril Cap · DIN 02308363 · 1.25 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ramipril Cap · DIN 02308363
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-06-14
Health Canada: Marketed since 2018-04-26 · brand RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRamipril Cap: Formulary list price $0.07 per unit (the source does not state the unit; exact figure $0.0708). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02308363)
Source record
DIN 02308363: Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id SIV
Source form: None; strength: 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0708; ministry $0.0708
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02308363
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79402
Interchangeable products
Altace Cap · DIN 02221829 · $0.0708
Apo-Ramipril Cap · DIN 02251515 · $0.0708
Auro-Ramipril Cap · DIN 02387387 · $0.0708
Co Ramipril Cap · DIN 02295482 · $0.0708
Jamp-Ramipril Cap · DIN 02331101 · $0.0708
Mar-Ramipril Cap · DIN 02420457 · $0.0708
PMS-Ramipril Cap · DIN 02295369 · $0.0708
PMSC-Ramipril Cap · DIN 02550202 · $0.0708
Pharma-Ramipril · DIN 02469057 · $0.0708
Ramipril Cap · DIN 02299372 · not recorded
Ran-Ramipril Cap · DIN 02310503 · $0.0708
Shortage status: resolved shortage (ended December 30, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02308363
Shortage record checked October 6, 2026
Ran-Ramipril Cap · DIN 02310503 · 1.25 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Ramipril Cap · DIN 02310503
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2008-11-04
Health Canada: Marketed since 2020-02-10 · brand TARO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRan-Ramipril Cap: Formulary list price $0.07 per unit (the source does not state the unit; exact figure $0.0708). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02310503)
Source record
DIN 02310503: Ran-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id RAN
Source form: None; strength: 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0708; ministry $0.0708
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02310503
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79613
Interchangeable products
Altace Cap · DIN 02221829 · $0.0708
Apo-Ramipril Cap · DIN 02251515 · $0.0708
Auro-Ramipril Cap · DIN 02387387 · $0.0708
Co Ramipril Cap · DIN 02295482 · $0.0708
Jamp-Ramipril Cap · DIN 02331101 · $0.0708
Mar-Ramipril Cap · DIN 02420457 · $0.0708
PMS-Ramipril Cap · DIN 02295369 · $0.0708
PMSC-Ramipril Cap · DIN 02550202 · $0.0708
Pharma-Ramipril · DIN 02469057 · $0.0708
Ramipril Cap · DIN 02299372 · not recorded
Ramipril Cap · DIN 02308363 · $0.0708
Shortage status: resolved shortage (ended January 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02310503
Shortage record checked October 6, 2026
AG-Ramipril Cap · DIN 02477572 · 2.5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Ramipril Cap · DIN 02477572
Manufacturer: Angita Pharma Inc.; listing date 2020-11-30
Health Canada: Marketed since 2018-09-06 · brand AG-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Angita pharma inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAG-Ramipril Cap: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02477572)
Source record
DIN 02477572: AG-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id ANG
Source form: None; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02477572
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96784
Interchangeable products
Altace Cap · DIN 02221837 · $0.0817
Apo-Ramipril Cap · DIN 02251531 · $0.0817
Auro-Ramipril Cap · DIN 02387395 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Jamp-Ramipril Cap · DIN 02331128 · $0.0817
Mar-Ramipril Cap · DIN 02420465 · $0.0817
Mint-Ramipril Cap · DIN 02421305 · $0.0817
NRA-Ramipril Cap · DIN 02486172 · $0.0817
PMSC-Ramipril Cap · DIN 02550210 · $0.0817
Pharma-Ramipril · DIN 02469065 · $0.0817
Ramipril Cap · DIN 02255316 · not recorded
Ramipril Cap · DIN 02287927 · $0.0817
Ramipril Cap · DIN 02374846 · $0.0817
Ran-Ramipril Cap · DIN 02310511 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02477572
Shortage record checked October 6, 2026
Altace Cap · DIN 02221837 · 2.5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Altace Cap · DIN 02221837
Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-06
Health Canada: Marketed since 2021-01-11 · brand ALTACE · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02221837)
Source record
DIN 02221837: Altace Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id SAV
Source form: None; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.1281; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02221837
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43309
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817
Apo-Ramipril Cap · DIN 02251531 · $0.0817
Auro-Ramipril Cap · DIN 02387395 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Jamp-Ramipril Cap · DIN 02331128 · $0.0817
Mar-Ramipril Cap · DIN 02420465 · $0.0817
Mint-Ramipril Cap · DIN 02421305 · $0.0817
NRA-Ramipril Cap · DIN 02486172 · $0.0817
PMSC-Ramipril Cap · DIN 02550210 · $0.0817
Pharma-Ramipril · DIN 02469065 · $0.0817
Ramipril Cap · DIN 02255316 · not recorded
Ramipril Cap · DIN 02287927 · $0.0817
Ramipril Cap · DIN 02374846 · $0.0817
Ran-Ramipril Cap · DIN 02310511 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended October 7, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02221837
Shortage record checked October 6, 2026
Apo-Ramipril Cap · DIN 02251531 · 2.5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Ramipril Cap · DIN 02251531
Manufacturer: Apotex Inc.; listing date 2007-03-09
Health Canada: Marketed since 2006-12-12 · brand APO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Ramipril Cap: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02251531)
Source record
DIN 02251531: Apo-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id APX
Source form: None; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02251531
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73646
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817
Altace Cap · DIN 02221837 · $0.0817
Auro-Ramipril Cap · DIN 02387395 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Jamp-Ramipril Cap · DIN 02331128 · $0.0817
Mar-Ramipril Cap · DIN 02420465 · $0.0817
Mint-Ramipril Cap · DIN 02421305 · $0.0817
NRA-Ramipril Cap · DIN 02486172 · $0.0817
PMSC-Ramipril Cap · DIN 02550210 · $0.0817
Pharma-Ramipril · DIN 02469065 · $0.0817
Ramipril Cap · DIN 02255316 · not recorded
Ramipril Cap · DIN 02287927 · $0.0817
Ramipril Cap · DIN 02374846 · $0.0817
Ran-Ramipril Cap · DIN 02310511 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: active shortage (reported June 16, 2026, estimated to end October 9, 2026, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02251531
Shortage record checked October 6, 2026
Auro-Ramipril Cap · DIN 02387395 · 2.5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Ramipril Cap · DIN 02387395
Manufacturer: Auro Pharma Inc.; listing date 2013-02-28
Health Canada: Marketed since 2012-09-13 · brand AURO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Ramipril Cap: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02387395)
Source record
DIN 02387395: Auro-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id AUR
Source form: None; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02387395
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87298
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817
Altace Cap · DIN 02221837 · $0.0817
Apo-Ramipril Cap · DIN 02251531 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Jamp-Ramipril Cap · DIN 02331128 · $0.0817
Mar-Ramipril Cap · DIN 02420465 · $0.0817
Mint-Ramipril Cap · DIN 02421305 · $0.0817
NRA-Ramipril Cap · DIN 02486172 · $0.0817
PMSC-Ramipril Cap · DIN 02550210 · $0.0817
Pharma-Ramipril · DIN 02469065 · $0.0817
Ramipril Cap · DIN 02255316 · not recorded
Ramipril Cap · DIN 02287927 · $0.0817
Ramipril Cap · DIN 02374846 · $0.0817
Ran-Ramipril Cap · DIN 02310511 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended December 13, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02387395
Shortage record checked October 6, 2026
Jamp-Ramipril Cap · DIN 02331128 · 2.5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Ramipril Cap · DIN 02331128
Manufacturer: Jamp Pharma Corporation; listing date 2010-04-23
Health Canada: Marketed since 2026-09-01 · brand JAMP RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Ramipril Cap: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02331128)
Source record
DIN 02331128: Jamp-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id JPC
Source form: None; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02331128
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81684
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817
Altace Cap · DIN 02221837 · $0.0817
Apo-Ramipril Cap · DIN 02251531 · $0.0817
Auro-Ramipril Cap · DIN 02387395 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Mar-Ramipril Cap · DIN 02420465 · $0.0817
Mint-Ramipril Cap · DIN 02421305 · $0.0817
NRA-Ramipril Cap · DIN 02486172 · $0.0817
PMSC-Ramipril Cap · DIN 02550210 · $0.0817
Pharma-Ramipril · DIN 02469065 · $0.0817
Ramipril Cap · DIN 02255316 · not recorded
Ramipril Cap · DIN 02287927 · $0.0817
Ramipril Cap · DIN 02374846 · $0.0817
Ran-Ramipril Cap · DIN 02310511 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended November 8, 2017); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02331128
Shortage record checked October 6, 2026
Mar-Ramipril Cap · DIN 02420465 · 2.5 mg ·
General benefitMarketed · checked November 19, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Ramipril Cap · DIN 02420465
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-05-29
Health Canada: Marketed since 2015-01-09 · brand MAR-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMar-Ramipril Cap: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02420465)
Source record
DIN 02420465: Mar-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id MAR
Source form: None; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02420465
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90505
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817
Altace Cap · DIN 02221837 · $0.0817
Apo-Ramipril Cap · DIN 02251531 · $0.0817
Auro-Ramipril Cap · DIN 02387395 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Jamp-Ramipril Cap · DIN 02331128 · $0.0817
Mint-Ramipril Cap · DIN 02421305 · $0.0817
NRA-Ramipril Cap · DIN 02486172 · $0.0817
PMSC-Ramipril Cap · DIN 02550210 · $0.0817
Pharma-Ramipril · DIN 02469065 · $0.0817
Ramipril Cap · DIN 02255316 · not recorded
Ramipril Cap · DIN 02287927 · $0.0817
Ramipril Cap · DIN 02374846 · $0.0817
Ran-Ramipril Cap · DIN 02310511 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended July 31, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02420465
Shortage record checked October 6, 2026
Mint-Ramipril Cap · DIN 02421305 · 2.5 mg ·
General benefitMarketed · checked November 19, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Ramipril Cap · DIN 02421305
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-06-26
Health Canada: Marketed since 2014-03-17 · brand MINT-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Ramipril Cap: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02421305)
Source record
DIN 02421305: Mint-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id MIN
Source form: None; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02421305
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90594
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817
Altace Cap · DIN 02221837 · $0.0817
Apo-Ramipril Cap · DIN 02251531 · $0.0817
Auro-Ramipril Cap · DIN 02387395 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Jamp-Ramipril Cap · DIN 02331128 · $0.0817
Mar-Ramipril Cap · DIN 02420465 · $0.0817
NRA-Ramipril Cap · DIN 02486172 · $0.0817
PMSC-Ramipril Cap · DIN 02550210 · $0.0817
Pharma-Ramipril · DIN 02469065 · $0.0817
Ramipril Cap · DIN 02255316 · not recorded
Ramipril Cap · DIN 02287927 · $0.0817
Ramipril Cap · DIN 02374846 · $0.0817
Ran-Ramipril Cap · DIN 02310511 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02421305
Shortage record checked October 6, 2026
NRA-Ramipril Cap · DIN 02486172 · 2.5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Ramipril Cap · DIN 02486172
Manufacturer: Nora Pharma; listing date 2020-09-30
Health Canada: Marketed since 2019-09-20 · brand NRA-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Ramipril Cap: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02486172)
Source record
DIN 02486172: NRA-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id NRA
Source form: None; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02486172
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97640
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817
Altace Cap · DIN 02221837 · $0.0817
Apo-Ramipril Cap · DIN 02251531 · $0.0817
Auro-Ramipril Cap · DIN 02387395 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Jamp-Ramipril Cap · DIN 02331128 · $0.0817
Mar-Ramipril Cap · DIN 02420465 · $0.0817
Mint-Ramipril Cap · DIN 02421305 · $0.0817
PMSC-Ramipril Cap · DIN 02550210 · $0.0817
Pharma-Ramipril · DIN 02469065 · $0.0817
Ramipril Cap · DIN 02255316 · not recorded
Ramipril Cap · DIN 02287927 · $0.0817
Ramipril Cap · DIN 02374846 · $0.0817
Ran-Ramipril Cap · DIN 02310511 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02486172
Shortage record checked October 6, 2026
PMSC-Ramipril Cap · DIN 02550210 · 2.5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMSC-Ramipril Cap · DIN 02550210
Manufacturer: Pharmascience Inc.; listing date 2025-12-30
Health Canada: Marketed since 2025-10-03 · brand PMSC-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMSC-Ramipril Cap: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02550210)
Source record
DIN 02550210: PMSC-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id PMS
Source form: None; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02550210
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103905
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817
Altace Cap · DIN 02221837 · $0.0817
Apo-Ramipril Cap · DIN 02251531 · $0.0817
Auro-Ramipril Cap · DIN 02387395 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Jamp-Ramipril Cap · DIN 02331128 · $0.0817
Mar-Ramipril Cap · DIN 02420465 · $0.0817
Mint-Ramipril Cap · DIN 02421305 · $0.0817
NRA-Ramipril Cap · DIN 02486172 · $0.0817
Pharma-Ramipril · DIN 02469065 · $0.0817
Ramipril Cap · DIN 02255316 · not recorded
Ramipril Cap · DIN 02287927 · $0.0817
Ramipril Cap · DIN 02374846 · $0.0817
Ran-Ramipril Cap · DIN 02310511 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550210
Shortage record checked October 6, 2026
Pharma-Ramipril · DIN 02469065 · 2.5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Pharma-Ramipril · DIN 02469065
Manufacturer: Pharmascience Inc.; listing date 2018-09-27
Health Canada: Marketed since 2018-04-16 · brand PHARMA-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPharma-Ramipril: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02469065)
Source record
DIN 02469065: Pharma-Ramipril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id PMS
Source form: None; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02469065
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95771
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817
Altace Cap · DIN 02221837 · $0.0817
Apo-Ramipril Cap · DIN 02251531 · $0.0817
Auro-Ramipril Cap · DIN 02387395 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Jamp-Ramipril Cap · DIN 02331128 · $0.0817
Mar-Ramipril Cap · DIN 02420465 · $0.0817
Mint-Ramipril Cap · DIN 02421305 · $0.0817
NRA-Ramipril Cap · DIN 02486172 · $0.0817
PMSC-Ramipril Cap · DIN 02550210 · $0.0817
Ramipril Cap · DIN 02255316 · not recorded
Ramipril Cap · DIN 02287927 · $0.0817
Ramipril Cap · DIN 02374846 · $0.0817
Ran-Ramipril Cap · DIN 02310511 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02469065
Shortage record checked October 6, 2026
Ramipril Cap · DIN 02287927 · 2.5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ramipril Cap · DIN 02287927
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-06-14
Health Canada: Marketed since 2018-04-26 · brand RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRamipril Cap: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02287927)
Source record
DIN 02287927: Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id SIV
Source form: None; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02287927
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77332
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817
Altace Cap · DIN 02221837 · $0.0817
Apo-Ramipril Cap · DIN 02251531 · $0.0817
Auro-Ramipril Cap · DIN 02387395 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Jamp-Ramipril Cap · DIN 02331128 · $0.0817
Mar-Ramipril Cap · DIN 02420465 · $0.0817
Mint-Ramipril Cap · DIN 02421305 · $0.0817
NRA-Ramipril Cap · DIN 02486172 · $0.0817
PMSC-Ramipril Cap · DIN 02550210 · $0.0817
Pharma-Ramipril · DIN 02469065 · $0.0817
Ramipril Cap · DIN 02255316 · not recorded
Ramipril Cap · DIN 02374846 · $0.0817
Ran-Ramipril Cap · DIN 02310511 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended July 6, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02287927
Shortage record checked October 6, 2026
Ran-Ramipril Cap · DIN 02310511 · 2.5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Ramipril Cap · DIN 02310511
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2008-11-04
Health Canada: Marketed since 2020-02-10 · brand TARO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRan-Ramipril Cap: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02310511)
Source record
DIN 02310511: Ran-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id RAN
Source form: None; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02310511
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79614
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817
Altace Cap · DIN 02221837 · $0.0817
Apo-Ramipril Cap · DIN 02251531 · $0.0817
Auro-Ramipril Cap · DIN 02387395 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Jamp-Ramipril Cap · DIN 02331128 · $0.0817
Mar-Ramipril Cap · DIN 02420465 · $0.0817
Mint-Ramipril Cap · DIN 02421305 · $0.0817
NRA-Ramipril Cap · DIN 02486172 · $0.0817
PMSC-Ramipril Cap · DIN 02550210 · $0.0817
Pharma-Ramipril · DIN 02469065 · $0.0817
Ramipril Cap · DIN 02255316 · not recorded
Ramipril Cap · DIN 02287927 · $0.0817
Ramipril Cap · DIN 02374846 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended January 21, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02310511
Shortage record checked October 6, 2026
Teva-Ramipril Cap · DIN 02247945 · 2.5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Ramipril Cap · DIN 02247945
Manufacturer: Teva Canada Limited; listing date 2007-06-06
Health Canada: Marketed since 2010-05-27 · brand TEVA-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Ramipril Cap: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247945)
Source record
DIN 02247945: Teva-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id TEV
Source form: None; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247945
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72255
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817
Altace Cap · DIN 02221837 · $0.0817
Apo-Ramipril Cap · DIN 02251531 · $0.0817
Auro-Ramipril Cap · DIN 02387395 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Jamp-Ramipril Cap · DIN 02331128 · $0.0817
Mar-Ramipril Cap · DIN 02420465 · $0.0817
Mint-Ramipril Cap · DIN 02421305 · $0.0817
NRA-Ramipril Cap · DIN 02486172 · $0.0817
PMSC-Ramipril Cap · DIN 02550210 · $0.0817
Pharma-Ramipril · DIN 02469065 · $0.0817
Ramipril Cap · DIN 02255316 · not recorded
Ramipril Cap · DIN 02287927 · $0.0817
Ramipril Cap · DIN 02374846 · $0.0817
Ran-Ramipril Cap · DIN 02310511 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Shortage status: shortage reported ended May 5, 2026 (report last updated May 5, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247945
Shortage record checked October 6, 2026
AG-Ramipril Cap · DIN 02477580 · 5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Ramipril Cap · DIN 02477580
Manufacturer: Angita Pharma Inc.; listing date 2020-11-30
Health Canada: Marketed since 2018-09-06 · brand AG-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 5 MG · company Angita pharma inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAG-Ramipril Cap: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02477580)
Source record
DIN 02477580: AG-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800205; group id 350; item number 0804; lccId None; manufacturer id ANG
Source form: None; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02477580
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96785
Interchangeable products
Altace Cap · DIN 02221845 · $0.0817
Apo-Ramipril Cap · DIN 02251574 · $0.0817
Auro-Ramipril Cap · DIN 02387409 · $0.0817
Co Ramipril Cap · DIN 02295504 · $0.0817
Jamp-Ramipril Cap · DIN 02331136 · $0.0817
Mar-Ramipril Cap · DIN 02420473 · $0.0817
Mint-Ramipril Cap · DIN 02421313 · $0.0817
NRA-Ramipril Cap · DIN 02486180 · $0.0817
PMSC-Ramipril Cap · DIN 02550229 · $0.0817
Pharma-Ramipril · DIN 02469073 · $0.0817
Ramipril Cap · DIN 02255324 · not recorded
Ramipril Cap · DIN 02287935 · $0.0817
Ramipril Cap · DIN 02374854 · $0.0817
Ran-Ramipril Cap · DIN 02310538 · $0.0817
Teva-Ramipril Cap · DIN 02247946 · $0.0817
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02477580
Shortage record checked October 6, 2026
Altace Cap · DIN 02221845 · 5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Altace Cap · DIN 02221845
Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-06
Health Canada: Marketed since 2021-01-11 · brand ALTACE · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 5 MG · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02221845)
Source record
DIN 02221845: Altace Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800205; group id 350; item number 0804; lccId None; manufacturer id SAV
Source form: None; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.1575; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02221845
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43310
Interchangeable products
AG-Ramipril Cap · DIN 02477580 · $0.0817
Apo-Ramipril Cap · DIN 02251574 · $0.0817
Auro-Ramipril Cap · DIN 02387409 · $0.0817
Co Ramipril Cap · DIN 02295504 · $0.0817
Jamp-Ramipril Cap · DIN 02331136 · $0.0817
Mar-Ramipril Cap · DIN 02420473 · $0.0817
Mint-Ramipril Cap · DIN 02421313 · $0.0817
NRA-Ramipril Cap · DIN 02486180 · $0.0817
PMSC-Ramipril Cap · DIN 02550229 · $0.0817
Pharma-Ramipril · DIN 02469073 · $0.0817
Ramipril Cap · DIN 02255324 · not recorded
Ramipril Cap · DIN 02287935 · $0.0817
Ramipril Cap · DIN 02374854 · $0.0817
Ran-Ramipril Cap · DIN 02310538 · $0.0817
Teva-Ramipril Cap · DIN 02247946 · $0.0817
Shortage status: resolved shortage (ended February 15, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02221845
Shortage record checked October 6, 2026
Apo-Ramipril Cap · DIN 02251574 · 5 mg ·
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Ramipril Cap · DIN 02251574
Manufacturer: Apotex Inc.; listing date 2007-03-09
Health Canada: Marketed since 2006-12-12 · brand APO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 5 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Ramipril Cap: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0817). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02251574)
Source record
DIN 02251574: Apo-Ramipril Cap
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800205; group id 350; item number 0804; lccId None; manufacturer id APX
Source form: None; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0817; ministry $0.0817
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02251574
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73648
Interchangeable products
AG-Ramipril Cap · DIN 02477580 · $0.0817
Altace Cap · DIN 02221845 · $0.0817
Auro-Ramipril Cap · DIN 02387409 · $0.0817
Co Ramipril Cap · DIN 02295504 · $0.0817
Jamp-Ramipril Cap · DIN 02331136 · $0.0817
Mar-Ramipril Cap · DIN 02420473 · $0.0817
Mint-Ramipril Cap · DIN 02421313 · $0.0817
NRA-Ramipril Cap · DIN 02486180 · $0.0817
PMSC-Ramipril Cap · DIN 02550229 · $0.0817
Pharma-Ramipril · DIN 02469073 · $0.0817
Ramipril Cap · DIN 02255324 · not recorded
Ramipril Cap · DIN 02287935 · $0.0817
Ramipril Cap · DIN 02374854 · $0.0817
Ran-Ramipril Cap · DIN 02310538 · $0.0817
Teva-Ramipril Cap · DIN 02247946 · $0.0817
Shortage status: resolved shortage (ended September 10, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02251574
Shortage record checked October 6, 2026
Ramipril Cap · DIN 02255316 · 2.5 mg ·
Listed, not a benefitMarketed · checked October 5, 2026
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ramipril Cap · DIN 02255316
Manufacturer: Laboratoire Riva Inc.; listing date 2008-08-28
Health Canada: Marketed since 2017-11-13 · brand RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Laboratoire riva inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRamipril Cap: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02255316)
Source record
DIN 02255316: Ramipril Cap
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id RIA
Source form: None; strength: 2.5mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02255316
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74047
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817
Altace Cap · DIN 02221837 · $0.0817
Apo-Ramipril Cap · DIN 02251531 · $0.0817
Auro-Ramipril Cap · DIN 02387395 · $0.0817
Co Ramipril Cap · DIN 02295490 · $0.0817
Jamp-Ramipril Cap · DIN 02331128 · $0.0817
Mar-Ramipril Cap · DIN 02420465 · $0.0817
Mint-Ramipril Cap · DIN 02421305 · $0.0817
NRA-Ramipril Cap · DIN 02486172 · $0.0817
PMSC-Ramipril Cap · DIN 02550210 · $0.0817
Pharma-Ramipril · DIN 02469065 · $0.0817
Ramipril Cap · DIN 02287927 · $0.0817
Ramipril Cap · DIN 02374846 · $0.0817
Ran-Ramipril Cap · DIN 02310511 · $0.0817
Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended June 20, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02255316
Shortage record checked October 6, 2026
Other products in the same Health Canada class (C09AA): coverage varies; not interchangeable
- Benazepril (Lotensin): general benefit, not a benefit
- Captopril (Noyada): general benefit, limited Use 707, 723, not a benefit
- Cilazapril (Inhibace): general benefit, not a benefit
- Enalapril (Vasotec): general benefit, not a benefit
- Fosinopril (Monopril): general benefit, not a benefit
- Lisinopril (Prinivil): general benefit, not a benefit
3 more in the class list below
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered
Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE
Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL
24:08 Hypotensive Drugs (For Diuretics See 40:28)
· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab
· 14 products ·
Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab
· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab
· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab
· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab
· 45 products · Listed, not a benefit (1), General benefit (44) · strengths: 5mg, 10mg, 20mg · Tab
· 48 products · General benefit · strengths: 2mg, 4mg, 8mg · Tab
· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 5mg, 10mg, 20mg, 40mg · Tab
· 26 products · Off-Formulary Interchangeable, not an ODB benefit (4), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (18), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab
· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab
· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:08
and 34 more
Full class listing
Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors
Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE
ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6)
INDICATIONS AND CLINICAL USE
APO-ACEBUTOLOL is indicated for the following:
Treatment of mild to moderate hypertension.
Long-term management of patients with angina pectoris due to ischemic heart disease.
PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10
Product monograph
AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (46)
1 INDICATIONS
NORVASC (amlodipine besylate tablets) is indicated for:
• Hypertension
NORVASC is indicated in the treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10
Product monograph
AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit
1 Part 1: Healthcare Professional Information Indications
• EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the
treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10
Product monograph
BENAZEPRIL · Listed, not a benefit (3), General benefit (3)
Indications
BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:
Treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10
Product monograph
CANDESARTAN CILEXETIL · General benefit
• Heart Failure
o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in
addition to standard therapy, with or without an ACE inhibitor.
1.1 Pediatrics
Pediatrics (6 to 17 years of age):
• Hypertension
ATACAND is indicated for the treatment of essential hypertension in children and
adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS).
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monograph
• Hypertension
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monograph
CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit
1 INDICATIONS
ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for:
• the treatment of essential hypertension in patients for whom combination therapy is
appropriate.
PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10
Product monograph
CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2)
1 INDICATIONS
APO-CHLORTHALIDONE (chlorthalidone) is indicated for:
• Treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10
Product monograph
CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit
1 INDICATIONS
INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:
treatment of mild to moderate essential hypertension in patients for whom combination therapy
with both cilazapril and hydrochlorothiazide is appropriate.
PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10
Product monograph
CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8)
INDICATIONS AND CLINICAL USE
TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10
Product monograph
ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit
1 INDICATIONS
VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:
Treatment of essential hypertension in patients for whom this combination therapy with
enalapril and hydrochlorothiazide is appropriate.
PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10
Product monograph
and 20 more
Coverage source: ON formulary extract 2026-09-22